Clinical Trials Logo

Clinical Trial Summary

Heart failure with preserved ejection fraction (HFpEF) is the fastest growing form of heart failure with a high morbidity and mortality rate, and is associated with severe exercise intolerance. The mechanisms responsible for the reduced exercise tolerance remain poorly understood. The investigators propose a novel paradigm shift, focusing on peripheral limitations to exercise. In particular, the investigators will test the hypothesis that muscle sympathetic nerve activity (MSNA) is elevated in older HFpEF patients compared to healthy controls, and is associated with reduced exercise tolerance. The investigators will also test whether 16-weeks of exercise training will lower MSNA compared to attention control, and correlate with improved exercise tolerance in older HFpEF patients.


Clinical Trial Description

Heart failure with preserved ejection fraction is the fastest growing form of heart failure, is almost exclusively found in older persons, particularly older women, and is associated with a high morbidity and mortality rate. The primary chronic symptom in HFpEF patients is severe exercise intolerance measured objectively as decreased peak exercise oxygen uptake (peak VO2). A consequence of the reduced exercise tolerance is that activities of daily living require near maximal effort, resulting in further deconditioning and reduced quality of life. The majority of work to date has focused on cardiac limitations, showing impaired cardiac output and marked diastolic dysfunction. Although these findings have provided important insight into the pathophysiology of HFpEF, drug therapies targeting cardiac function do not improve peak VO2, quality of life, or survival in HFpEF patients.

Older HFpEF patients have multiple skeletal muscle abnormalities including reduced skeletal muscle oxidative capacity and capillary-to-fiber ratio resulting in increased anaerobic metabolism during low-level exercise. Importantly, accumulation of anaerobic metabolites within the exercising muscles are known to activate skeletal muscle afferent fibers (called metaboreceptors), that elicit a reflex-mediated increase in efferent muscle sympathetic (vasoconstrictor) nerve activity (MSNA). The investigators here propose a novel paradigm of exercise intolerance in older HFpEF patients whereby skeletal muscle abnormalities lead to overactivation of the muscle metaboreflex and MSNA mediated vasoconstriction that limits delivery of oxygenated blood to the active muscles. Further, exercise training mediated improvements in skeletal muscle function will alleviate the metaboreflex, thereby reducing MSNA and improve oxygen delivery to the contracting muscles.

To test this novel paradigm, the investigators will first perform an initial cross-sectional comparison of older (≥60 years) HFpEF patients (N=24) with age and sex-matched healthy controls (N=24), and then enter the HFpEF patients into a randomized, controlled, single blind, trial of exercise training to test the following hypothesis: (i) that MSNA is elevated in older HFpEF patients compared to healthy controls, and is associated with reduced peak VO2, physical functional performance, aerobic endurance, muscle blood flow, and quality of life; and (ii) Exercise training will attenuate MSNA compared to attention control, and will correlate with improved peak VO2, physical functional performance, aerobic endurance, muscle blood flow, and quality of life in older HFpEF patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03111017
Study type Interventional
Source The University of Texas at Arlington
Contact
Status Completed
Phase N/A
Start date April 17, 2017
Completion date December 12, 2019

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04573166 - Personalized Atrial Septostomy for Heart Failure N/A
Recruiting NCT02425371 - Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years) Phase 3
Terminated NCT03312387 - Muscle, Essential Amino Acids, and eXercise in Heart Failure N/A
Completed NCT05475028 - Network Medicine Approaches to Classify Heart Failure With PReserved Ejection Fraction by Signatures of DNA Methylation and Point-of-carE Risk calculaTors (PRESMET)
Recruiting NCT04950218 - The Psoriasis Echo Study
Completed NCT02334891 - Kyoto Congestive Heart Failure Study
Recruiting NCT05577819 - Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF N/A
Completed NCT05139472 - Impact of Empagliflozin on Functional Capacity in Heart Failure With Preserved Ejection Fraction Phase 3
Recruiting NCT04682704 - The Effect of Different Low-Level Tragus Stimulation Parameters On Autonomic Nervous System Function N/A
Completed NCT03924479 - Respiratory Muscle Function in Heart Failure N/A
Recruiting NCT03830957 - Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker N/A
Completed NCT02589977 - Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF Phase 4
Completed NCT02946476 - Prognostic Impact of Noncardiac Comorbidities in Heart Failure Patients N/A
Recruiting NCT04179643 - NAN-101 in Patients With Class III Heart Failure Phase 1
Recruiting NCT05425459 - RESPONDER-HF Trial N/A
Completed NCT04940312 - MyoMobile Study: App-based Activity Coaching in Patients With Heart Failure and Preserved Ejection Fraction
Recruiting NCT04602338 - Diagnosis and OutcoMes evaluAtIoN of Multicenter Patients With HFpEF Using Multimodality Imaging
Completed NCT03240237 - CCM in Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT05887271 - A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction Phase 2/Phase 3
Recruiting NCT05479669 - Value of Intense Phenotyping in Heart Failure With Preserved Ejection Fraction